New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Olema Oncology

Contributing Author

Recent Articles by Olema Oncology

Oct-18	Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 OLMA GlobeNewswire
Oct-02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Sep-03	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Sep-02	Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer OLMA GlobeNewswire
Aug-20	Olema Oncology to Participate in Upcoming Investor Conferences OLMA GlobeNewswire
Aug-11	Olema Oncology Reports Second Quarter 2025 Financial and Operating Results OLMA GlobeNewswire
Aug-04	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Jul-02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
Jun-03	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire
May-28	Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting OLMA GlobeNewswire
May-21	Olema Oncology to Participate in Upcoming Investor Conferences OLMA GlobeNewswire
May-13	Olema Oncology Reports First Quarter 2025 Financial and Operating Results OLMA GlobeNewswire
May-09	Olema Oncology to Participate in Upcoming Investor Conferences OLMA GlobeNewswire
May-02	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) OLMA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.